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The pro-inﬂammatory cytokine thymic stromal lymphopoietin (TSLP) is pivotal to the
pathophysiology of widespread allergic diseases mediated by type 2 helper T cell (Th2)
responses, including asthma and atopic dermatitis. The emergence of human TSLP as a
clinical target against asthma calls for maximally harnessing its therapeutic potential via
structural and mechanistic considerations. Here we employ an integrative experimental
approach focusing on productive and antagonized TSLP complexes and free cytokine. We
reveal how cognate receptor TSLPR allosterically activates TSLP to potentiate the recruitment
of the shared interleukin 7 receptor a-chain (IL-7Ra) by leveraging the ﬂexibility, con-
formational heterogeneity and electrostatics of the cytokine. We further show that the
monoclonal antibody Tezepelumab partly exploits these principles to neutralize TSLP activity.
Finally, we introduce a fusion protein comprising a tandem of the TSLPR and IL-7Ra extra-
cellular domains, which harnesses the mechanistic intricacies of the TSLP-driven receptor
complex to manifest high antagonistic potency.
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T
hymic stromal lymphopoietin (TSLP)1,2, is an interleukin-2
(IL-2) family cytokine produced in response to pathogenic
stimuli by skin keratinocytes and epithelial cells in the lung
and gut. It regulates immunity at barrier surfaces by driving the
activation of immature dendritic cells (DCs), mast cells, basophils,
eosinophils and lymphocytes into a type 2 polarizing phenotype3,4.
TSLP initiates intracellular signalling by establishing a complex
with its speciﬁc receptor, TSLPR (encoded by CRLF2) (refs 5,6)
and IL-7Ra. Notably, the latter also serves together with
the common gamma-chain (gc) receptor in signalling
complexes driven by IL-7 to regulate T-cell development and
homoeostasis7.
The downside of aberrant signalling by TSLP has grave
consequences for human health and imprints a massive
healthcare and socioeconomic footprint. This is because type 2
helper T cell (Th2)-mediated inﬂammatory responses primed by
activated DCs, are pivotal for the onset of widespread allergic
diseases of the airways, skin and gut8. In fact, TSLP is now widely
considered to underlie some of the most prevalent inﬂammatory
allergic disorders, such as the atopic diseases (asthma, atopic
dermatitis and atopic rhinitis), chronic obstructive pulmonary
disease (COPD) and eosinophilic esophagitis9–12, and has been
annotated as a genetic risk factor for the development of
asthma13–15 and eosinophilic esophagitis16. Furthermore, a
staggering 70% of atopic dermatitis clinical cases go on to
develop asthma via the ‘allergic march’ (also known as ‘atopic
march’)17, and adult asthmatics are strongly predisposed for
acquiring COPD (ref. 18). Several recent developments have
expanded the pathophysiological proﬁle of TSLP. First, TSLP was
shown to provide a signalling link between the skin epithelium
and neuronal cells to trigger itch associated with atopic
dermatitis19. Second, TSLP was shown to contribute to the
development of psoriasis, a widespread autoimmune disease, by
regulating IL-23 production by DCs20. Third, TSLP may drive
tumour progression in breast- and pancreatic cancer21,22 but also
manifest tumour protective effects23–26, while genetic
rearrangements and mutations in the TSLPR gene (CRLF2) are
found in paediatric acute lymphoblastic leukaemia (ALL)27.
However, the role of TSLP in cancer is controversial8,28. Fourth,
TSLP was shown to upregulate IL-9 production in vivo to
promote Th9 cell-induced allergic inﬂammation suggesting a
possible interplay between the two cytokines and their hallmark
Th2 and Th9 responses in allergy29. Finally, TSLP has been linked
to neutrophil-mediated killing of bacteria trough interactions
with the complement system30.
Such a broad pathophysiology proﬁle and the soaring rates of
atopic and autoimmune diseases in the second half of the 20th
century have motivated therapeutic targeting of TSLP and TSLP-
mediated signalling31,32. For instance, blockade of TSLPR in a
primate animal model was shown to attenuate allergic
inﬂammation33, and TSLP was shown to be pivotal for the
development of resistance to corticosteroid treatment during
airway inﬂammation34. More recently, the combinatorial ablation
of TSLP, IL-25 and IL-33 has displayed therapeutic potential in
mouse disease models of inﬂammation and ﬁbrosis35. Notably,
the validity of TSLP as a therapeutic target in humans was
demonstrated in a clinical trial in which asthmatic patients were
treated with an anti-TSLP monoclonal antibody36.
In this study, we delineate the molecular, structural and
mechanistic principles underpinning the extracellular assembly of
the pro-inﬂammatory signalling complex driven by human TSLP
and its antagonism by the therapeutic monoclonal antibody
Tezepelumab (AMG-157/MEDI9929). We further describe the
development of fusion proteins featuring tandem arrangements of
the ectodomains of human TSLPR and IL-7Ra as potent
antagonists of human TSLP signalling.
Results
Reconstitution and cooperativity of the TSLP complex. Prior
studies had suggested that the signalling complex mediated by
human TSLP proceeds through an initial binary complex between
TSLP and TSLPR to enable recruitment of IL-7Ra (refs 5,6,37). To
determine the assembly order and kinetic proﬁle underlying the
TSLP:TSLPR:IL-7Ra complex we performed real time in vitro
interaction studies via bio-layer interferometry (BLI) using
mammalian-derived glycosylated TSLP, IL-7 and soluble TSLPR
and IL-7Ra (Supplementary Fig. 1A). In accordance to prior
observations human TSLP could only be produced in HEK293
cells upon abolishing its putative furin cleavage site38. Firstly, we
determined that TSLPR binds to TSLP with high-afﬁnity
(KD¼ 32nM) and fast kinetics (ka¼ 1.7 105 M 1 s 1 and
kd¼ 5.2 10 3 s 1) (Fig. 1a). In contrast, IL-7Ra, which was
able to bind to cognate IL-7 (Supplementary Fig. 1B), showed no
apparent binding to TSLP alone (Fig. 1b)39. However, IL-7Ra
associated with preformed TSLP:TSLPR binary complex with high-
afﬁnity (KD¼ 29nM; ka of 1.23 105M 1 s 1; kd of
3.6 10 3 s 1) (Fig. 1c). Thus, priming of human TSLP by its
cognate receptor, TSLPR, is a mechanistic prerequisite for the
recruitment of shared IL-7Ra to the extracellular ternary complex.
Such initial mechanistic insights formed the basis for a strategy
to biochemically reconstitute the TSLP:TSLPR:IL-7Ra complex
for structural studies. To facilitate the growth of well-diffracting
crystals towards structural characterization of the complex at
high-resolution by X-ray crystallography, we focused on the
production of minimally glycosylated ternary complexes. We thus
produced non-glycosylated bioactive human TSLP lacking a basic
cassette (127RRKRK131) (ref. 38) and the IL-7Ra ectodomain via
in vitro refolding from inclusion bodies produced in E. coli37,40.
In parallel, we were able to produce N-glycosylation variants of
TSLPR (TSLPRN47Q, TSLPRN47Q/N101Q and TSLPRN47Q/N169Q)
in HEK293S-TetR MGAT1 / cells41,42. Following enzymatic
trimming of residual TSLPR glycosylation, ternary TSLP:
TSLPR:IL-7Ra complexes were assembled and isolated in a
sequential manner by size-exclusion chromatography (SEC)
(Fig. 1d,e), and were found to be highly homogeneous (Fig. 1f)
and to adopt monodisperse assemblies obeying 1:1:1
stoichiometry as characterized by coupling SEC to multi-angle
laser light scattering (MALLS) (Fig. 1g). Crystallization trials
using puriﬁed TSLPD127–131:TSLPRN47Q:IL-7Ra complex lead to
optimized crystals that diffracted synchrotron X-rays to 2.55Å
resolution, and enabled determination of the crystal structure of
the human TSLP:TSLPR:IL-7Ra complex by molecular
replacement (Fig. 1h, Table 1).
TSLP evokes receptor–receptor interactions. Our crystal-
lographic analysis contributes structural insights at high-resolu-
tion of human TSLP and TSLPR (Supplementary Fig. 1C) and
reveals how TSLP wedges between TSLPR and IL-7Ra to mediate
a T-shaped extracellular assembly (Fig. 2a), as further supported
by small-angle X-ray scattering (Supplementary Fig. 2;
Supplementary Table 1). TSLP employs two opposing surface
patches to interact with the elbow tips of the cytokine-binding
homology regions (CHRs) of TSLPR (site I) and IL-7Ra (site II),
which allow the membrane-proximal parts of the two receptors to
engage in heterotypic receptor–receptor interactions (site III)
(Fig. 2a). TSLP and TSLPR display pronounced electrostatic
complementarity spanning the entire site I, with TSLP presenting
a positively charged surface patch associating with the negatively
charged interdomain elbow of TSLPR (Fig. 2b). This suggests that
long-range electrostatic interactions may play an important role
in attracting TSLP to TSLPR at the cell surface to establish the
mechanistically critical binary complex. Interestingly, electrostatic
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potential calculations on the TSLP:TSLPR binary complex show
that this molecular entity would project a negative electrostatic
potential, which would render it compatible with the positive
electrostatic potential of unbound IL-7Ra.
Consistent with annotations of human TSLP as a member of the
IL-2 family of cytokines, its mature sequence (residues
29–159) adopts a four-helix bundle with ‘up-up-down-down’
topology stabilized by three disulﬁde bridges (Cys34-Cys110,
Cys69-Cys75 and Cys90-Cys137), in which the four a-helices—
designated aA, aB, aC, aD—are threaded via a BC loop and two
long overhand AB and CD loop regions, with the latter largely
invisible in the electron density maps (Fig. 2a; Supplementary
Fig. 3A). The functional role of the ﬂexible CD loop containing the
seven residue basic cassette (residues 125–131) remains enigmatic
(Supplementary Fig. 3A). It has been hypothesized that its
embedded furin cleavage site is linked to a mechanism limiting
the availability of proinﬂammatory TSLP in vivo43. Moreover, it
was recently shown that in nasal polyp tissues this loop region can
be proteolytically processed to yield a biologically active nicked
form of human TSLP (ref. 44). In addition, the positive charge
density may mediate interactions with glycosoaminoglycans in the
extracellular matrix, as proposed for IL-7 (ref. 45).
The structure of human TSLP is unique among helix bundle
cytokines in three main ways. First, it adopts a rather open helix
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Figure 1 | The TSLP signalling complex assembles via a cooperative stepwise mechanism. (a–c) BLI data traces (black) and ﬁtted 1:1 binding model (red)
are plotted as the spectral nanometre shift in function of time for the interaction of TSLPR with TSLP (a), IL-7Ra with TSLP (b) and IL-7Ra with preformed
TSLP:TSLPR complex (c). 4 nm of biotinylated TSLP was loaded for experiments (a–c). In experiment (c) TSLP-coated biosensors were incubated with
320 nM TSLPR and 320nM of TSLPR was included in kinetics buffer and IL-7Ra samples. The reported KD-, ka- and kd-values represent average values and
their s.d. from three technical replicate experiments. (d) SEC elution proﬁles on a Superdex 75 16/600 column of EndoH-treated TSLPRN47Q (dashed line)
and TSLPD127–131:TSLPRN47Q complex (solid line) plotted as the ultraviolet absorbance at 280 nm in function of elution volume. (e) SEC elution proﬁle on a
Superdex 200 16/600 column of TSLPD127–131:TSLPRN47Q:IL-7Ra complex plotted as the ultraviolet absorbance at 280 nm in function of elution volume.
(f) Coomassie-stained reducing SDS–PAGE gel of glycan-minimized ternary complex used for crystallization trials. The theoretical protein molecular
weights for IL-7Ra, TSLPR and TSLP are 25.7, 24.0 and 14.6 kDa. (g) SEC elution proﬁle on a Superdex-200 10/300 GL column of glycan-minimized ternary
TSLP complex plotted as the ultraviolet absorbance at 280 nm (left Y-axis) as a function of elution volume. The molecular weight (right Y-axis) as
determined by MALLS is reported as the number average molecular mass and its s.d. (h) Crystals of the TSLPD127–131:TSLPRN47Q:IL-7Ra complex.
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bundle core that is perforated by an elongated internal void
volume (B120Å3) running from the aA-aC face to the aB-aC
face of the helical bundle (Fig. 2c). Second, it harbours a fully
buried structural water at the heart of the helical bundle,
coordinated by a conserved trio of amino acids (Trp148, Thr102,
Thr83) (Fig. 2c; Supplementary Fig. 3A) suggesting that this
central water molecule is an integral part of the protein fold. This
notion is supported by molecular dynamics (MD) simulations of
TSLP using an explicit solvent model, whereby TSLP devoid of
this core water molecule rapidly acquires a new water molecule
from solvent through a water channel between helices B and C
(Supplementary Fig. 3B). Third, the conspicuously kinked aA in
TSLP, a structural feature shared with IL-7 despite the lack of
appreciable levels of sequence identity (Fig. 2d, Supplementary
Fig. 3C), is hallmarked by a p-helical turn. Interestingly, MD
simulations showed that in about 20% of the simulated frames a
water molecule inserted into the p-helical turn of TSLP,
seemingly to compensate for the interrupted hydrogen-bonding
pattern of the main chain (Supplementary Fig. 3D), reminiscent
of water-mediated stabilization of p-helical turns in diverse
proteins46.
The AB loop in TSLP relays IL-7Ra recruitment. The atypical
open helical bundle core of TSLP and the intriguing p-helical turn
in helix aA of TSLP prompted us to hypothesize that the priming
of TSLP by TSLPR for recruitment of IL-7Ra might be linked to
the intrinsic plasticity and dynamics of TSLP. To this end, we
performed a series of nuclear magnetic resonance (NMR)
experiments on isotopically labelled TSLPD127–131 and pursued
complementary MD simulations. Assignment of the NMR spectra
by triple resonance spectroscopy on isotopically labelled
TSLPD127–131 revealed that unbound TSLP comprises the four a-
helices as delineated in the structure of TSLP bound to its
receptors (Fig. 2e). Furthermore, 1H–15N heteronuclear NOE
analysis showed decreased NOE values for the overhand AB and
CD loops, as well as for the N- and C-termini, reﬂecting the
relative higher ﬂexibility of these regions compared to the helical
parts of the structure47 (Fig. 2f).
Altogether with the structure of receptor-bound TSLP, these
ﬁndings provide the rationale for tracing possible structural
transitions in TSLP upon complex formation. In particular,
TSLP employs the C-terminal half of aD (residues 142–152), the
C-terminal short tail extending from aD (residues 153–158) and
a continuous stretch of 10 residues located in the long overhand
AB-loop region (residues 60–69) to interact with a complemen-
tary interaction epitope formed at the elbow tip of the CHR-
module of TSLPR (Fig. 2a; Supplementary Table 2). On the basis
of our NMR studies, the AB-loop and C-terminal tail would
undergo signiﬁcant conformational changes to achieve their
observed bound state. This is additionally supported by
extensive MD simulations for TSLP and TSLP:TSLPR
(Fig. 2g,h), and might have profound mechanistic implications.
This is because the AB loop provides a physical link to aA,
which in turn is central to deﬁning site II and the interactions of
TSLP with IL-7Ra (Fig. 2a). Thus, our ﬁndings point to the
possible role of the AB loop as a structural liaison between the
two receptor binding sites on TSLPR (sites I and II) poised to
relay a binding event to TSLPR at site I to prime TSLP for the
cooperative recruitment of IL-7Ra at site II.
Table 1 | X-ray data set and reﬁnement statistics*,w.
TSLP:TSLPR:IL-7Ra complex TSLP:Fab complex
Data collection
Source Proxima 2A (SOLEIL, France) Proxima 2A (SOLEIL, France)
Detector ADSC QUANTUM 315r EIGER 9M
Wavelength (Å) 0.98 0.98
Space group C 2 P 32 1 2
Cell dimensions
a, b, c (Å) 135.8, 66.6, 92.0 51.7, 51.7, 370.0
a,b, g () 90.0, 109.2, 90.0 90.0, 90.0, 120.0
Resolution (Å) 50.0–2.56 (2.72–2.56) 55.0–2.30 (2.44–2.30)
zWilson B (Å2) 69.9 47.33
Completeness (%) 97.8 (94.2) 97.0 (83.8)
Redundancy 3.2 (3.1) 8.4 (4.2)
Mean I/s(I) 14.2 (1.7) 14.23 (1.6)
Rmeas (%) 6.2 (77.6) 11.0 (74.7)
CC1/2 (%) 99.8 (78.2) 99.8 (64.2)
wReﬁnement
Resolution (Å) 45.76–2.56 (2.67–2.56) 44.80–2.30 (2.39–2.30)
No. reﬂections 24,638 (2,738) 25,275 (2,306)
Rwork/Rfree 0.1912/0.2176 (0.2674/0.3351) 0.1891/0.2150 (0.3078/0.3914)
No. non-H atoms 4,033 4,120
Protein 3,966 3,997
Ligands 38 15
Water 29 108
Average ADP (Å2) 89.40 51.90
Protein 89.30 52.00
Ligands 118.30 67.60
Water 69.70 48.50
r.m.s.d.’s
Bond lengths (Å) 0.014 0.003
Bond angles () 1.71 0.77
*Values in parentheses correspond to the highest-resolution shell.
wFinal reﬁnement was performed in autoBuster 2.10.2 for the TSLP:TSLPR:IL-7Ra complex and in PHENIX 1.9-1692 for the TSLP:Fab complex.
zMaximum likelihood estimate of the Wilson B-factor from phenix.xtriage.
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Figure 2 | Structure of the TSLP:TSLPR:IL-7Ra complex and TSLP structural dynamics. (a) View of the determined X-ray structure for the TSLP:TSLPR:IL-7Ra
complex. TSLP (blue) is shown in cartoon representation with its four helices labelled as aA to aD. TSLP loop regions are highlighted in red with the disordered CD
loop region represented as a dashed line. The extracellular regions of TSLPR (yellow) and IL-7Ra (grey), each comprising two FnIII-like domains, D1 and D2, are shown
as cartoons overlaid onto transparent surface representations. TSLPR and IL-7Ra strand and loop regions contributing to sites I, II and III are labelled. Disulﬁde bridges
are shown as yellow spheres. The water molecule in the core of TSLP is shown as a red sphere. Modelled GlcNAc moieties on TSLPR are shown as grey sticks. The
C-terminal loop extending from TSLPR strand G2 is coloured purple. BSA: buried surface area. (b) Bottom and side view cartoon representations of the TSLP complex
with the electrostatic potential at the solvent accessible surfaces shown for TSLP (top) and TSLPR (bottom). (c) The coordinated water molecule in the bundle core
(red sphere) is located adjacent to an elongated internal void volume (pink mesh). (d) Structural comparison of human TSLP (blue) as seen in the TSLP:TSLPR:IL-7Ra
complex and human IL-7 (orange) as seen in the IL-7:IL-7Ra complex (pdb 3DI2, chain A). (e) 13C-consensus chemical shift index (CSI) analysis of TSLPD127–131. The
location of crystallographically observed a-helices in the TSLP:TSLPR:IL-7Ra complex as annotated by DSSP is schematically shown on top with the p-helical turn
coloured in red. (f) Backbone 15N–1H heteronuclear NOE values measured on f TSLPD127–131 plotted as a function of TSLP residue number. Data points for residues in
the p-helical turn are coloured red. (g) Snapshot for one of ﬁve different 250ns MD simulations runs for full-length TSLP is shown as a cartoon. Residues are coloured
according to their average root mean square ﬂuctuations (r.m.s.f.) of backbone positions over the ﬁve different MD runs. The width of the cartoon loop radius varies
with the r.m.s.f. value. (h) Average backbone r.m.s.f. values and s.d. (shaded region) for unbound TSLP (black) and for TSLP in complex with TSLPR (red) plotted in
function of TSLP residue number. Average r.m.s.f. values and s.d. were calculated from ﬁve 250ns MD-runs, each with a different starting model for TSLP.
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Our NMR analysis show that among all residues deﬁning the
four a-helices of TSLP, Thr46 and Ile47 in the p-helical turn
midway aA exhibit the highest degree of ﬂexibility in unbound
TSLP (Fig. 2f), yet they become well-ordered at the TSLP:IL-7Ra
interface. We therefore wondered about the origin of the
structural features of the atypical aA of TSLP and about its
possible role in IL-7Ra recruitment. Indeed, analysis of the NOE
strips through each of the resonances of residues in aA showed
that the relative intensity of the amide-amide proton cross peak
compared to the diagonal peak is 15–25% for all amide proton
pairs, except for the Thr46 HN—Ile47 HN NOE where the
normalized cross peak rises to 54% (Supplementary Fig. 3E). This
discrepancy agrees with the distances between consecutive amide
protons in aA in the bound state of TSLP, which measure at the
expected 2.7±0.1 Å throughout aA, except for the helical kink
region, where the Thr46 HN—Ile47 HN distance shortens to
2.1 Å, while the adjacent Ile47 HN-Ser48 HN distance increases to
2.9 Å. Thus, unbound TSLP in solution also displays the kinked
aA and associated p-helical turn character before engaging to
TSLPR and IL-7Ra. The mechanistic ramiﬁcations of this
deduction are large. In the context of a TSLP helical bundle core
that is not densely packed, the TSLP:TSLPR binary complex
might facilitate positioning of aA relayed by the AB loop and
the tethering of aA via Leu44 to TSLPR. This can be expected to
provide an entropic advantage for recruiting IL-7Ra to the
ternary complex.
TSLP and TSLPR interact via an extensive polar interface. The
extracellular domain of TSLPR (residues 25–230) carries a single
CHR module composed of two tandem ﬁbronectin type III (FnIII)-
domains, D1 and D2 (Fig. 2a). The membrane-distal TSLPRD1
domain is characterized by a ABED/C0CFG topology stabilized by
a Cys71-Cys84 disulﬁde bridge, while the membrane-proximal
TSLPRD2 domain displays a ABE/C0CFG topology with two dis-
ulﬁde bridges Cys138-Cys168 and Cys180-Cys218 (Fig. 2a). The
latter tethers Cys218 in the loop region extending from strand G2
in TSLPRD2 towards the transmembrane helix of TSLPR with
Cys180 located in strand F2 (Supplementary Fig. 4). Intriguingly,
TSLPR carries a solvent-accessible cysteine residue at position 208
in close proximity to disulﬁde bridge Cys180-Cys218. Although the
role of this unusual triangle of cysteine residues is currently
unknown, and while surface-exposed cysteines are rarely observed
in receptor ectodomains, disulﬁde-mediated linkage of TSLPR and
IL-7Ra in the context of somatic mutations in the juxtamembrane
and transmembrane domains has been connected to the patho-
physiology of B-ALL and T-ALL (refs 48,49).
Human TSLPR uses three regions to grasp TSLP and buries
B1,900Å2 of solvent exposed surface area: (1) the intersheet EF1
loop and N-terminal residues of the F strand of TSLPRD1
(residues 91–96), (2) the C-terminal residues of TSLPRD1 strand
G and the interdomain linker connecting TSLPRD1 and TSLPRD2
(residues 110–116) and (3) the a-helical turn located
in the FG2 loop of TSLPRD2 (residues 192–195), (Fig. 2a;
Supplementary Table 2). Altogether, the human TSLP cytokine-
receptor interface has a pronounced polar footprint and allows
us to trace the species-speciﬁcity of the TSLP:TSLPR interac-
tion37 (Supplementary Figs 3A and 5), providing a potentially key
resource towards interrogating human TSLP activity in mouse
models.
We subsequently leveraged such detailed structural informa-
tion to identify functional hotspots at the TSLP:TSLPR interface
(Fig. 3a) via cellular studies in vitro including a STAT5 activation
assay (Supplementary Table 3). Even though human TSLP has
been linked to a number of JAK-STAT signalling pathways,
STAT5 activation by TSLP has emerged as a signalling
prerequisite for Th2 responses mediated by TSLP (refs 4,50). In
a competition-based cellular TSLPR-binding assay employing
wild type TSLP fused to secreted alkaline phosphatase (TSLP-
SEAP) we ﬁrst identiﬁed a set of TSLP mutants that failed to
displace TSLP-SEAP from TSLPR (Fig. 3b). These TSLP mutants
probed the importance of the triplet of arginine residues near the
C-terminal region of TSLP at the TSLP:TSLPR interface (Arg149,
Arg150 and Arg153) (Fig. 3a). In TSLP-induced STAT5 activity
assays these TSLP mutants were still able to induce STAT5
activation, albeit with half maximal effective concentration (EC50)
values lowered by 1–3 orders of magnitude as compared with WT
(EC50¼ 0.15 pM). The TSLP-Arg149Ser/Arg150Ser double
mutant had the most pronounced effect (EC50¼ 100 pM)
(Fig. 3c). To probe the importance of TSLPR site I interface
residues we performed STAT5-based cellular activity assays with
a set of TSLPR variants (Supplementary Table 3). Here, TSLPR-
Asp92Ala, TSLPR-Trp112Ala and TSLPR-Trp112Arg displayed a
greater than 1,000-fold reduced EC50-value as compared to wild
type (Fig. 3d). The apparent essential roles of TSLPR-Asp92 and
TSLPR-Trp112 in TSLP recruitment are borne by our structural
observations. TSLPR-Asp92 pairs via a bifurcated hydrogen-bond
with TSLP-Arg153 and TSLP-Arg150, while Trp112 packs
between aD and the AB loop of TSLP (Fig. 3a).
IL-7Ra binds TSLP via a degenerate hydrophobic interface.
IL-7Ra performs a dual role at the cell surface: it constitutes the
high-afﬁnity receptor for IL-7 signalling, and functions as the
co-receptor for TSLP-mediated signalling (Supplementary
Fig. 6A). Our structural studies reveal that IL-7Ra employs a
hydrophobic platform contributed by several residues in IL-
7RaD1 (Val78, Leu100, Ile102) and IL-7RaD2 (Tyr159, Tyr212,
Phe213) to clamp onto the AC-face of the TSLP helical bundle
as deﬁned by residues protruding from aA of TSLP (Ala41,
Ala42, Leu44, Ser45, Thr46, Leu47, Lys49) and aC (Met97,
Met100, Lys101, Ala104, Ala105, Ile108 and Trp109) (Figs 2a
and 3e; Supplementary Table 2). With B1,120 Å2 of buried
solvent accessible surface area, the hydrophobic TSLP:IL-7Ra
interface (site II) is markedly more limited than the
TSLP:TSLPR interface (site I).
To interrogate the importance of TSLP residues at the TSLP:IL-
7Ra interface, we evaluated a set of TSLP variants carrying
mutations at site II (Supplementary Table 3). While our selected
set of single site TSLP mutants had no apparent effect, we found
that a double TSLP mutant carrying Ser45Arg/Thr46Arg
mutations at the p-helical turn of aA (Fig. 3f) showed reduced
capacity in inducing TSLPR/IL-7Ra-mediated STAT5-signalling
(EC50¼ 5.3 pM versus for IC50,WT¼ 0.11 pM), while the afﬁnity
towards TSLPR remained largely unaffected (IC50¼ 720 pM
versus IC50,WT¼ 320 pM) (Fig. 3g). At site II, mutations in the
hydrophobic EF loop region of IL-7RaD1 (Leu100Ser/Ile102Ser,
EC50¼ 470 pM) also led to a decreased signalling potential
(EC50¼ 85 pM) (Fig. 3d).
Comparisons with the human IL-7:IL-7Ra binary complex51
show that IL-7Ra adopts a highly similar structure in the two
complexes (r.m.s.d.¼ 0.66Å for 195 Ca atoms) and offers
preformed binding sites to either cytokine as evidenced by the
structure of IL-7Ra in the absence of cytokine (Supplementary
Fig. 6B). Although IL-7 and TSLP exhibit marginal sequence
similarity (Supplementary Fig. 3C), IL-7Ra employs a near identical
set of residues to interact with IL-7 and TSLP, burying 740Å2 and
630Å2 of solvent-accessible surface, respectively (Supplementary
Fig. 6C,D). Thus, the cytokine binding degeneracy of IL-7Ra
originates from a promiscuous hydrophobic platform at the IL-7Ra
elbow tip combined with unique structural features shared between
the TSLP and IL-7 cytokines.
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Receptor–receptor interactions potentiate TSLP signalling.
One of the observed hallmarks of the receptor complex mediated
by human TSLP concerns the compact network of interactions
between the membrane-proximal regions of TSLPRD2 and IL-
7RaD2 (Figs 2a and 4a; Supplementary Table 2). The ensuing
heterotypic receptor interface buries B780Å2 of solvent-acces-
sible surface area contributed by the AB2, CC02 and EF2 loops of
TSLPRD2, and the ABE2-face, and AB2 and EF2 loops of IL-
7RaD2. The interface displays several electrostatic interactions
and close van der Waals contacts, such as the packing of TSLPR-
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Figure 3 | Structure-based dissection of TSLP cytokine-receptor interfaces. (a) Detail of the TSLP:TSLPR interface (site I). Interface residues are shown
as sticks. Water molecules are shown as red spheres. Hydrogen bonds and salt bridges are indicated with a dashed line. (b) Competitive binding assay
measuring displacement by either wild type (WT) or mutated TSLP of bound TSLP-SEAP fusion protein from HEK293Tcells expressing TSLPR. (c) STAT5
activity induced by WT or mutated TSLP, as measured using a luciferase-based reporter system in HEK293T cells expressing WT TSLPR and IL-7Ra. The
EC50-values were 0.15 pM for TSLP-WT, 2.8 pM for TSLP-Arg149Ser, 9.5 pM for TSLP-Arg150Ser, 100 pM for TSLP-Arg149Ser/Arg150Ser and 19 pM for
TSLP-Arg153Ser. (d) TSLP-induced STAT5 activity assay in cells expressing WTor mutant forms of either TSLPR or IL-7Ra. The EC50-values were 85 pM for
the control, 87 nM for TSLPR-Asp92Ala and 470pM for IL-7Ra-Leu100Ser/Ile102Ser. For mutants TSLPR-Trp112Ala and TSLPR-Trp112Arg the EC50-value
could not be accurately determined. (e) Detail of the TSLP:IL-7Ra interface (site II). Interface residues are shown as sticks. Water molecules are shown as
red spheres. Hydrogen bonds and salt bridges are indicated with a dashed line. (f) STAT5 activity induced by WT or TSLP-Ser45Arg/Thr46Arg in cells
expressing wild-type TSLPR and IL-7Ra. The EC50 values were 0.11 pM for TSLP-WT and 5.3 pM for TSLP-Ser45Arg/Thr46Arg. (g) Competitive binding
assay measuring displacement by either WT (IC50¼ 320pM) or TSLP-Ser45Arg/Thr46Arg (EC50¼ 720pM) from bound TSLP-SEAP fusion protein from
HEK293T cells expressing TSLPR. Each experiment was carried out in triplicate; data shown are averages, and error bars were calculated as s.e.m.
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Phe156 against a hydrophobic patch deﬁned by Gly142 and
Ala143 in the AB2-loop of IL-7RaD2 at the base of the interface
(Fig. 4b).
To evaluate the importance of the heterotypic TSLPR:IL-7Ra
interactions for TSLP-induced signalling we evaluated a set of
TSLPR site III mutants via our STAT5-activation assays (Fig. 4b).
While single-site site III mutants of TSLPR (Supplementary
Table 3) had no apparent effect, combinations of mutations in the
CC02 loop (Asp157Ala/Glu159Ala and Phe156Ala/Asp157Ala/
Glu159Ala) or EF2 loop (Asp176Ala/Glu178Ala/Lys179Ala) of
TSLPRD2 (Fig. 4a) showed decreased STAT5 activity as
compared to wild type TSLPR. These results indicate that
TSLPRD2:IL-7RaD2 interactions are required for efﬁcient activa-
tion of TSLP-induced signalling. We next probed the potential
interaction between the receptor ectodomains in the absence of
TSLP and measured a low, albeit appreciable, afﬁnity (KD¼ 20
mM), contrasting the lack of any measurable interaction between
the TSLPR ectodomains (Fig. 4c,d). This suggests that TSLPR and
IL-7Ra are predisposed to interact under certain conditions at the
cell membrane and might provide the basis for rationalizing
the mechanism of disease-related mutations localizing in the
membrane-proximal regions of the two receptors52.
Receptor fusion proteins are potent TSLP antagonists. TSLP is
increasingly gaining a central role in the pathophysiology of
allergic diseases. To identify novel TSLP antagonists, we designed
TSLP cytokine traps53 by fusing the TSLPR and IL-7Ra
extracellular regions in both orientations with a ﬂexible
(Gly-Gly-Ser)20-linker, hereafter termed TSLP-trap1 and TSLP-
trap2 (Fig. 5a), and produced them in stably transfected T-Rex-293
cells (Fig. 5b,c; Supplementary Fig. 7A). We found that TSLP-trap1
binds 250-fold stronger to TSLP (KD¼ 120 pM) (Fig. 5d) than
the unlinked receptor ectodomains do (Fig. 1c). Importantly, the
corresponding kinetic proﬁle shows that such high-afﬁnity can be
traced to a drastically reduced dissociation rate constant
(kd¼ 2 10 5 s 1) as compared to the dissociation rate of the
unfused ectodomains (Fig. 1c). A similar binding proﬁle was
observed for TSLP-trap2 (data not shown).
To compare the binding properties of our TSLP-traps to
Tezepelumab (AMG-157/MEDI9929) (ref. 54), to our knowledge
the most potent anti-TSLP antagonist to date, we produced AMG-
157 and its Fab fragment in HEK293T cells (Supplementary
Fig. 8A,B). AMG-157 is a fully human neutralizing immunoglo-
bulin G subclass 2 (IgG2) anti-TSLP monoclonal antibody (mAb)
and was recently shown to alleviate most measures of both early
and late asthmatic responses in patients with mild allergic
asthma36. AMG-157Fab displays comparable afﬁnity and binding
kinetics to TSLP when compared to TSLP-trap1 (Fig. 5e).
However, cellular activity assays in HEK293T cells at 10pM
TSLP (EC50¼ 9 pM) demonstrated that TSLP-trap1 and TSLP-
trap2 are 20–30 fold more potent in inhibiting TSLP-induced
STAT5 signalling (IC50¼ 67 and 44pM, respectively) (Fig. 5f,
Supplementary Fig. 7B) compared to AMG-157 mAb and its
Fab fragment (IC50¼ 1.4 and 1.7 nM, respectively) (Fig. 5f).
Remarkably, the TSLP-traps show about 1,000-fold higher
inhibitory potency over equimolar mixtures of unlinked TSLPR
and IL-7Ra (IC50¼ 49nM) (Fig. 5g), suggesting that fusion of the
two receptor ectodomains harnesses certain key mechanistic
features underlying the TSLP-receptor complex. Parallel assays at
100 pM TSLP resulted in analogous observations but with overall
higher IC50-values (Supplementary Fig. 7C). Finally, neither TSLP-
trap1 nor TSLP-trap2 inhibited STAT5 signalling in HEK293T
cells transfected with IL-7Ra and the common gamma-chain (gc)
mediated by IL-7 at 10 and 100 pM (EC50¼ 41 pM) (Fig. 5h;
Supplementary Fig. 7D,E).
To evaluate the potential of TSLP-traps to block TSLP-driven
dendritic cell activation we quantiﬁed HLA-DR, CD40 and CD80
cell-surface expression levels and CCL17 chemokine production
by primary human CD1cþ blood dendritic cells treated with
TSLP alone3,36 or in combination with antagonists (Fig. 6a,b).
These experiments show that both TSLP-trap1 and TSLP-trap2
are able to signiﬁcantly inhibit TSLP-driven DC activation, and
that they are as potent in this regard as AMG-157.
Structure and mechanism of TSLP antagonism by Tezepelumab.
We seized the opportunity to obtain structural and mechanistic
insights into how Tezepelumab (AMG-157) might exert its
antagonistic effects on TSLP and to characterize TSLP in a binary
complex with a non-signalling binding partner, by pursuing the
crystal structure of TSLP in complex with AMG-157Fab. We were
able to biochemically reconstitute and crystallize the TSLPD127–131:
AMG-157Fab complex and to determine its crystal structure to 2.3Å
resolution (Fig. 7a; Table 1, Supplementary Fig. 8D). The structure
reveals that the complementarity determining regions (CDRs) of the
variable heavy chain domain (VH) of AMG-157 target TSLP at
the AB-loop region and C-terminal region of helix D, while the
variable light chain fragment does not interact with TSLP at all
(Fig. 7a). The TSLP:AMG-157 interface buries a total of 1,200Å2 of
accessible surface area, with all three VH-CDR loops contributing to
a polar footprint (Fig. 7b; Supplementary Table 4). Most notably,
Glu110 in the CDR-3 loop makes a bifurcated salt-bridge with
TSLP-Arg150 and TSLP-Arg153, and Trp105 packs against TSLP-
Cys75 in a surface pocket formed between TSLP aD and the
overhand AB-loop (Fig. 7b). Importantly, we now show that AMG-
157 competes against a critical part of the TSLPR binding site on
TSLP and remains completely clear of the IL-7Ra binding site on the
other side of the TSLP helical bundle (Fig. 7c). Furthermore,
structural superposition of TSLP in its two complexes shows that the
AB-loop and C-terminal tail extending from aD adopt different
conformations, with the rest of the TSLP main chain being very
similar (r.m.s.d. of 0.56Å for 89 aligned Ca atoms). In fact the AB-
loop and the C-terminal tail of aD in the TSLP:AMG-157 complex
are only partly resolved in the electron density maps, indicating that
these regions are ﬂexible in the absence of TSLPR consistent with
our NMR and MD studies of TSLP (Figs 2f and 7d).
Plasticity and functional role of the p-helix turn in TSLP. The
TSLP:AMG-157 complex provides a unique view of the IL-7Ra
binding site on TSLP in the absence of the shared receptor,
thereby fuelling insights into the possible structural transitions
associated with the cooperative recruitment of IL-7Ra to the
TSLP-mediated signalling complex. Perhaps the most intriguing
feature of TSLP as bound to AMG-157 concerns an ordered water
molecule that inserts into the p-helical turn of helix aA in TSLP
to provide a hydrogen-bonded bridge between the main-chain
carbonyl and amide groups of Tyr43 and Lys49 (Fig. 7e). Such
compensatory structural feature against the local disruption of the
helix hydrogen bonding network has been linked to the stabili-
zation of p-helical elements46,55. In accommodating the observed
water molecule, the p-helical turn in aA in the TSLP:AMG-157
complex is wider by about 1.5 Å than in the TSLP:TSLPR:IL-7Ra
complex (Fig. 7e). Thus, the p-helical turn in aA is able to adopt
at least two distinct conformational states. Given the localization
of this part of aA at the crossroads of the TSLP:TSLPR:IL-7Ra
complex (Fig. 2a) and its contribution to the IL-7Ra binding
epitope (Fig. 3e), we propose that the observed structural
plasticity at the p-helical turn in aA may be a key feature in
the structural priming of the cytokine by TSLPR to enable high-
afﬁnity binding by IL-7Ra. In support of this notion and the
functional role of receptor–receptor interactions in the ternary
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14937 ARTICLE
NATURE COMMUNICATIONS | 8:14937 | DOI: 10.1038/ncomms14937 | www.nature.com/naturecommunications 9
complex, IL-7Ra cannot be recruited to the TSLP:AMG-157
complex (Supplementary Fig. 8C).
Additional insights into the possible structural states of TSLP
are provided by our NMR analysis. Close inspection of the
1H,15N HSQC TSLPD127–131 NMR spectrum at 900 MHz
uncovered conformational heterogeneity on the second time-
scale, which is much slower than can be sampled by MD-
simulations. Speciﬁcally, we identiﬁed two populations for the
Tyr43-Leu44-Ser45-Thr46 amide resonances located in the
p-helical turn in aA of TSLP, as well as for the side-chain
resonance of Trp148, which stacks right above the p-helical turn
of TSLP (Fig. 7f; Supplementary Fig. 9A–E). The minor
conformations observed for Ser45 and Trp148 are populated to
20±2% based on deconvoluted integrals of their respective
signals, suggesting that they represent the same structural
heterogeneity that connects the core of TSLP to aA. Although
our NMR analysis does not provide structural details for the two
TSLP conformations, together with the distinct conformational
states of active versus antagonized TSLP, it provides independent
support for the structural heterogeneity of TSLP.
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Discussion
The emergence of TSLP as a central orchestrator of Th2 responses
that initiate allergy and inﬂammation has placed therapeutic
targeting of TSLP-mediated signalling against major chronic diseases
such as allergic asthma and atopic dermatitis at center stage.
However, in order to maximally harness the therapeutic potential of
TSLP-mediated signalling, it will be essential to dissect the structural
and mechanistic basis for its bioactivity. Recent efforts that have
leveraged mechanistic and structure-based considerations of cyto-
kine-mediated receptor activation, have led to the development of
engineered IL-2, IL-4 and IL-13 variants with drastically improved
therapeutic efﬁcacy and speciﬁcity, illustrating the power of
consolidating such approaches in the development of tailor-made
biologics56–58. In this study we have employed an integrative
approach, including structural data at high-resolution, to propose a
mechanistic blueprint for the activation and antagonism of the pro-
inﬂammatory complex mediated by human TSLP.
The cornerstone of our mechanistic proposal is the high-
afﬁnity TSLP:TSLPR encounter complex driven by long-range
electrostatic attraction of TSLP to its speciﬁc receptor at the cell
surface, that primes two key concerted structural events: (i)
allosteric activation of TSLP at site II by restructuring of its
epicentre at the p-helical turn of aA relayed by the structuring of
the AB loop to enable recruitment of the shared receptor IL-7Ra
and (ii) positioning of the TSLPR membrane-proximal domain
to facilitate interactions with the corresponding extracellular
domain of IL-7Ra (Fig. 8). The latter is potentially facilitated
in part by the intrinsic, albeit low, afﬁnity of the two
receptors for each other, and partly by electrostatic attraction of
IL-7Ra to the TSLP:TSLPR binary complex, consistent with
mechanistic implementation seen in diverse families of cytokine
receptors58–60.
The intrinsic cooperativity of the TSLP:TSLPR:IL-7Ra complex
is also the mechanistic pillar for the high in vitro potency of the
TSLP-traps we have developed by linking the TSLPR and IL-7Ra
ectodomains to create a single protein. Our TSLP-trap fusion
proteins neutralize TSLP via a very drastic improvement in the
KD compared to the unlinked counterparts by nearly three orders
of magnitude (KD¼ 120 pM) manifested primarily by very slow
off-rate kinetics (t1/2B10 h). This strong increase in binding
afﬁnity is functionally reﬂected by the potent antagonistic activity
and speciﬁcity of the TSLP-traps against TSLP signalling in our
cellular inhibition assays with IC50-values below 100 pM (Fig. 5).
Such binding properties gain important biological context in light
of the ability of both TSLP-trap1 and TSLP-trap2 to effectively
antagonize TSLP-mediated molecular responses relevant for Th2
immunity in human primary cells (Fig. 6). Remarkably, the
IC50-values obtained for the TSLP-traps are 20–40-fold lower
than those obtained for the AMG-157 mAb and its derived
Fab fragment, which we propose is inextricably linked to the
mechanistic modalities of the TSLP-mediated receptor complex
(Fig. 8). Fusion proteins comprising receptor ectodomains and
decoy receptors foster attractive binding properties to serve as
effective therapeutics61, as exempliﬁed in the targeting of IL-1
(Rilonacept) or TNFa (Etanercept) for the treatment of CAPS-
syndrome and rheumatoid arthritis, respectively62. Indeed, we are
currently performing in vivo studies to assess the antagonistic
potency of such fusion proteins. Furthermore, we anticipate that
the current version of the TSLP-traps can be additionally
improved in a number of ways, including optimizing linker
length and introducing mutations to enhance the afﬁnity and/or
cross-linkage of the TSLPR and IL-7Ra ectodomains to each
other. Indeed, the therapeutic potential of targeting TSLP to treat
allergic diseases mediated by Th2 responses is large, in particular
in the context of combined approaches co-targeting the
bioactivity of IL-25 and IL-33 (ref. 35).
Finally, our work on human TSLP provides opportunities to
further investigate recent intriguing ﬁndings describing a second
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isoform of TSLP, termed short form TSLP (sfTSLP)63–65.
Evidence for sfTSLP mainly pertains to the transcriptional
levels of sfTSLP, and led to proposals that sfTSLP might be the
constitutively expressed isoform of TSLP. sfTSLP is 63 residues in
length and approximately covers the C-terminal half of human
TSLP (residues 97–159). On our structure of human TSLP,
sfTSLP would encompass aC, the long CD loop and aD
(Supplementary Fig. 3A). It is presently unclear if sfTSLP can
adopt any helical structure in the absence of aA and aB.
However, a propensity to form amphipathic helices combined
with a high isoelectric point (pI) of 11.1 would support its
presumed function as antimicrobial peptide63,66. sfTSLP may also
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exhibit anti-inﬂammatory properties64,65 and may mediate immune
tolerance in the gut67.
We envisage that the structural and mechanistic framework
and the molecular tools presented here will facilitate targeted
interrogation of TSLP signalling in vitro and in animal models,
and will guide therapeutic approaches that manipulate human
TSLP-mediated signalling to treat allergic diseases.
Methods
Protein expression in mammalian cells and puriﬁcation. HEK293T (ATCC
CRL-3216), HEK293S-TetR MGAT1 / (ref. 41) and T-REx-293 (Thermo Fisher
Scientiﬁc) cells were grown in high-glucose DMEM medium supplemented with
10% fetal calf serum, 106 units per l penicillin G and 1 g l 1 streptomycin in a 5%
CO2 atmosphere at 37 C. The medium of T-REx-293 cells was supplemented with
5 mgml 1 blasticidin. Mammalian expression constructs for secreted proteins
carrying a C-terminal hexahistidine-tag were generated in the pHLsec (ref. 68)
and/or pcDNA4/TO vector (Thermo Fisher Scientiﬁc). For transient expression
experiments 25 kDa branched PEI was used as transfection agent68. Before addition
of the PEI-DNA transfection mix, the medium of conﬂuently grown cells was
changed to serum-free medium. Post transfection of 3–4 days, secretion of
recombinant protein into the conditioned medium was conﬁrmed by western blot
analysis using an HRP-coupled antibody directed against the C-terminal His tag at
1:5,000 dilution ratio (Invitrogen, catalogue no. R931-25) and/or small-scale IMAC
puriﬁcations in batch mode using 2ml of conditioned medium.
Stable, tetracycline-inducible polyclonal cell lines for pcDNA4/TO expression
constructs were generated in HEK293S-TetR MGAT1 / cells or T-REx-293 cells
by selection with 200mgml 1 zeocin42. To induce expression the growth medium
of conﬂuently grown cells was replaced with serum-free medium supplemented
with 2 mgml 1 tetracycline. For large-scale expression experiments, HEK293T and
T-REx-293 cells were expanded to 850 cm2 roller bottles and HEK293S-TetR
MGAT1 / cells to 175 cm2 tissue-culture ﬂasks or 145 cm2 dishes. After 4–5
days following transient transfection or induction with tetracycline, the
conditioned medium was harvested and clariﬁed by centrifugation and ﬁltration
trough a 0.22 mm bottle top ﬁlter. Recombinant proteins were captured from the
clariﬁed conditioned medium by IMAC puriﬁcation using a cOmplete His-Tag
puriﬁcation column (Roche) and further puriﬁed by size-exclusion
chromatography using preparative grade HiLoad 16/600 Superdex 75/200 columns
(GE Healthcare) with HBS pH 7.4 as running buffer. Protein purity was evaluated
on Coomassie-stained SDS–polyacrylamide gel electrophoresis (SDS–PAGE) gels
(Figs 1f and 5b, Supplementary Figs 1A,8B and 10).
Production of TSLP and IL-7 and soluble TSLPR and IL-7Ra. Complementary
DNA (cDNA) fragments (Genscript) encoding full-length human TSLPR127A/R130S
(NP_149024.1; residue 1–159), human IL-7 (NP_000871.1; residue 1–177) and the
extracellular fragments of human TSLPR (NP_071431.2; residue 1–221) and
human IL-7Ra (NP_002176.2; residue 1–239) were cloned into the pHLsec and
pcDNA4/TO-expression vectors in frame with a C-terminal hexahistidine tag. The
R127A and R130S mutations in TSLP remove a potential furin cleavage site38. For
crystallization purposes, we also generated N-glycosylation mutants for TSLPR
(TSLPRN47Q, TSLPRN47Q/N101Q and TSLPRN47Q/N169Q). Single-site N47Q,
N101Q, N169Q mutants were ordered as synthetic genes from Genscript. The
TSLPRN47Q/N101Q variant was created by overlap extension PCR using primers 1–4
(Supplementary Table 5). The TSLPRN47Q/N169Q was generated by restriction-based
cloning. TSLPR-glycosylation variants were initially generated in the pHLsec-vector
for transient expression and later subcloned in the pcDNA4/TO vector. Stable,
tetracycline-inducible polyclonal cell lines for pcDNA4/TO expression constructs for
the TSLPR127A/R130S and IL-7 cytokines, and the TSLPR (TSLPRWT, TSLPRN47Q,
TSLPRN47Q/N101Q and TSLPRN47Q/N169Q) and IL-7Ra ectodomains were generated
in HEK293S-TetR MGAT1 / cells as described above.
Production of biotinylated TSLP and soluble TSLPR and IL-7Ra. To produce
biotinylated versions of TSLP, TSLPR and IL-7Ra cDNA fragments for
TSLPR127A/R130S, and the TSLPR and IL-7Ra ectodomains were cloned between
the EcoRI and KpnI sites of the pHL-AVITAG vector68. Before transfection in
HEK293T cells, the culture medium was changed to serum-free DMEM medium
supplemented with 100mM D-biotin. To allow speciﬁc C-terminal in vivo
biotinylation, pHL-AVITAG constructs were co-transfected with the pDisplay-BirA-
ER plasmid69 in a 5:1 ratio. The conditioned medium was harvested ﬁve days after
transfection and recombinant proteins were puriﬁed by IMAC and SEC.
Production of recombinant TSLP and IL-7Ra in E. coli. cDNA fragments
(Genscript) encoding human TSLPD127–131 (NP_149024.1; residue 29–159) and the
extracellular fragment of human IL-7Ra (NP_002176.2; residue 21–239) were
cloned in the pET15b expression vector in frame with a cleavable N-terminal
hexahistidine tag. TSLPD127–131 and IL-7Ra were expressed in the E. coli
BL21(DE3) strain as inclusion bodies and refolded in vitro40 using 6M Guanidine-
HCl as denaturing agent. Following refolding, the N-terminal His-tag was removed
using biotinylated thrombin (Novagen). Biotinylated thrombin was removed by
incubation with streptavidin agarose beads. Refolded proteins were further puriﬁed
by size-exclusion chromatography using a Superdex 75 column with HBS pH 7.4 as
running buffer.
Preparation of TSLP:TSLPR:IL-7Ra complex for crystallization. Following
puriﬁcation of TSLPRN47Q from stable HEK293S-TetR MGAT1 / cells,
N-linked glycosylation was trimmed by overnight incubation at room temperature
with EndoH (New England Biolabs) using 7.5 kU of EndoH per mg of complex.
The binary TSLP:TSLPRN47Q complex was formed by adding a molar excess of
refolded TSLPD127–131 to EndoH-treated TSLPRN47Q. The binary complex
TSLPD127–131:TSLPRN47Q was isolated and separated from the excess of TSLPD127–131
by SEC using a Superdex 75 column with HBS pH 7.4 as running buffer. The ternary
complex was then formed by adding a molar excess of the refolded IL-7Ra ectodomain
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to the binary TSLPD127–131:TSLPRN47Q complex. The ternary complex was isolated
and separated from the excess of IL-7Ra by SEC using a Superdex 200 column with
HBS pH 7.4 as running buffer. Fractions corresponding to the ternary TSLPD127–
131:TSLPRN47Q:IL-7Ra complex were pooled and concentrated by centrifugal ultra-
ﬁltration to a concentration of 6mgml 1. The protein sample was then aliquoted and
ﬂash frozen in liquid nitrogen.
Production of anti-TSLP mAb and Fab fragment and Fab:TSLP. cDNA frag-
ments (Gen9) encoding the Tezepelumab (AMG-157) lambda light chain, the IgG2
heavy chain54, and the PCR-derived VH-CH1 heavy chain fragment (primers 5 and
6) (Supplementary Table 5) were cloned between the AgeI and KpnI sites of the
pHLsec vector, in frame with the vector’s signal peptide. At the C-terminus, the
heavy chain and the VH-CH1 fragment carried a hexahistidine tag. The mAb and
its Fab-fragment were produced by co-transfecting HEK293T cells with expression
plasmids for the light chain and, heavy chain or VH-CH1-fragment in a 1:1 ratio.
The mAb or Fab-fragment were puriﬁed from the conditioned medium by IMAC
(Roche cOmplete column) and SEC (Superdex 200) using HBS pH 7.4 as running
buffer. The Fab:TSLP complex was formed by incubating the Fab-fragment with
a molar excess of refolded TSLPD127–131 produced in E. coli as described above.
The complex was then isolated from the molar excess of TSLPD127–131 by SEC and
concentrated to 10mgml 1. The protein sample was then aliquoted and ﬂash
frozen in liquid nitrogen.
Protein crystallization. Nanoliter-scale vapour diffusion crystallization experi-
ments were set up at 293K using a Mosquito crystallization robot (TTP Labtech)
and commercially available sparse-matrix screens (Molecular Dimensions,
Hampton research). The TSLPD127–131:TSLPRN47Q:IL-7Ra ternary complex crys-
tallized in condition H5 of the PEG/Ion HT screen (0.02M Citric acid, 0.08M BIS-
TRIS propane, pH 8.8, 16% w/v Polyethylene glycol 3,350). Following gradient
optimization, crystals were cryoprotected by a 1min soak into mother liquor
supplemented with 20% ethylene glycol. The TSLP:AMG-157Fab complex crystal-
lized in condition B8 of CrystalScreen HT (0.2M ammonium sulfate, 0.1M sodium
acetate pH 4.6 and 25% w/v polyethylene glycol 4,000) and crystals were cryo-
protected with mother liquor supplemented with 20% v/v polyethylene 400.
Crystals were cryo-cooled by direct plunging into liquid nitrogen.
Crystallographic structure determination. X-ray diffraction measurements were
conducted at the Proxima2A beam line (synchrotron SOLEIL, Gif-sur-Yvette,
France). All data were integrated and scaled using the XDS suite70. The structures
for the TSLPD127–131:TSLPRN47Q:IL-7Ra complex and the TSLPD127–131:AMG-
157Fab complex were determined by maximum-likelihood molecular replacement
(MR) as implemented in the program suite PHASER (ref. 71). Human TSLP and
TSLPR search models were derived from an X-ray structure for human
TSLP:TSLPR in complex with mouse IL-7Ra (PDB entry 5J12, to be published)
that was also solved by MR using search models derived from the mouse
TSLP:TSLPR:IL-7Ra complex (PDB entry 4NN5)37. The search model for human
IL-7Ra was obtained from the human IL-7:IL-7Ra complex (PDB entry 3DI2)51.
As a search model for the AMG-157Fab light chain, chain B of PDB entry 4HK0
was used, and for the AMG-157 heavy chain fragment, chain A of PDB entry 4HIE
was used. Both crystal forms contained one complex in their asymmetric unit.
Model (re)building was performed in COOT (ref. 72) and individual coordinate
and ADP reﬁnement (combined with TLS parameterization for the ternary
TSLP:TSLPR:IL-7Ra complex) was performed in PHENIX (ref. 73) and
autoBuster74. Model and map validation tools in COOT, the PHENIX suite and the
PDB_REDO server75 were used throughout the work ﬂow to guide improvement
and validate the quality of crystallographic models.
Disulﬁde determination in TSLPR. Following digestion of iodoacetamide-treated
TSLPR ectodomain with trypsin (sequencing grade modiﬁed trypsin, Promega,
V511), the peptide mixture was spotted onto an Opti-TOF 384 Well MALDI Plate
(ABsciex, Framingham, MA 01,701, USA, PN 10,16,629), in a 1:1 ratio mix with
MALDI matrix a-cyano-4-hydroxy cinnamic acid (Sigma, 4,76,870), prepared in a
concentration of 5mgml 1 in 0.1% triﬂuoroacetic acid, 10mM ammonium
citrate, 50% Acetonitrile. Sample MS and fragmentation spectra were acquired on a
4,800 Proteomics Analyzer, a MALDI-TOF-TOF instrument (ABsciex, Framing-
ham, MA 01,701, USA), using the delayed extraction and reﬂector technologies in
the positive ion mode. Default settings and factory acquisition methods were used.
The instrument was calibrated with Glu-Fibrinopeptide standards (Applied Bio-
systems 4,700 Proteomics Analyser Mass Standards kit, ABSciex, 43,33,604).
Design and production of TSLP-traps. The extracellular domains of human
TSLPR (NP_071431.2; residues 1–231) and human IL-7Ra (NP_002176.2; residues
1–239) were ampliﬁed by PCR using primer pairs 7–8 (TSLPR) and 9–10 (IL-7Ra),
respectively (Supplementary Table 5). The PCR fragments were cloned into the
EcoRI/XbaI opened pEF6-myc/HisA expression vector in frame with a C-terminal
myc/hexahistidine tag, resulting in pEF-ShTSLPR and pEF-ShIL7Ra. Human
TSLP-trap1 (pEF-hTSLPtrap1) was generated by PCR ampliﬁcation of a (GGS)20-
linker fragment from a plasmid template (primer pair 11–12) and the extracellular
part of the human IL-7Ra (residues 21–239) with the C-terminal myc/His tag from
pEF-ShIL7Ra with primer pair 13–14 (Supplementary Table 5). Both fragments
were ligated in frame by a 3-point ligation into the XbaI/PmeI opened pEF-
ShTSLPR vector. In the resulting fusion construct the human IL-7Ra extracellular
domain with C-terminal myc/His tag is connected by the (GGS)20-linker fragment
to the C-terminus of the human soluble TSLPR. Human TSLP-trap2 (pEF-
hTSLPtrap2) was generated likewise by ligating the same linker fragment together
with that encoding the extracellular domain of human TSLPR (residues 23–231
and C-terminal myc/His tag, PCR ampliﬁed from pEF-ShTSLPR with primer pair
14–15) into the XbaI/PmeI opened pEF-ShIL7Ra vector (Supplementary Table 5).
Finally, the natural signal sequence of hIL7Ra was replaced by subcloning the open
reading frame of hTSLPtrap2 (starting with residue E21 of the mature hIL7Ra
sequence) by PCR-cloning (primer pair 16–17) (Supplementary Table 5) into
EcoRI/PmeI of pEF6-ssFlag which contains the signal sequence of the murine IL-
33Ra followed by a Flag-tag. The ﬁnal expression vectors were generated by
cloning the cDNA-fragments encoding TSLP-trap1 and TSLP-trap2 into the
multicloning site of the the pcDNA4/TO-expression vector (Thermoﬁsher) in
frame with a C-terminal hexahistidine tag using primer pairs 18–19 and 20–21
(Supplementary Table 5). For TSLP-trap1, the native secretion signal of human
TSLPR was used, while for TSLP-trap2 the signal peptide from the pHLsec-vector
was used68. Stable, inducible cell lines for TSLP-trap1 and TSLP-trap2 were
generated in T-REx-293 cells as described above.
SEC-MALLS. Protein samples (100 ml) were injected onto a Superdex 200 Increase
10/300 GL column (GE Healthcare), with HBS pH 7.4 as running buffer at
0.5mlmin 1, coupled to an online ultraviolet-detector (Shimadzu), a multi-angle
light scattering miniDAWN TREOS instrument (Wyatt) and a Optilab T-rEX
refractometer (Wyatt) at 25 C. A refractive index increment (dn/dc) value of
0.185ml g 1 was used for protein concentration and molecular mass determina-
tion. Data were analysed using the ASTRA6 software (Wyatt). Correction for band
broadening was applied using parameters derived from BSA injected under iden-
tical running conditions. For the analysis of TSLP-traps, conjugate analysis was
performed using theoretical protein extinction coefﬁcients and a dn/dc-value of
0.160ml g 1 for the glycan modiﬁer.
Biolayer interferometry. BLI experiments were performed in PBS-buffer sup-
plemented with 0.01% (w/v) BSA and 0.002% (v/v) Tween 20, with an Octet
RED96 instrument (Forte´Bio), operating at 25 C. Streptavidin-coated biosensors
were functionalized with biotinylated TSLPR127A/R130S, TSLPR or IL-7Ra and
quenched with a 10mgml 1 biotin solution and then dipped into solutions con-
taining different analyte concentrations. IL-7, TSLPR and IL-7Ra ectodomains
produced from stable transfected HEK293S-TetR MGAT / cells were used as
analyte. To verify that no non-speciﬁc binding was present during the interaction
assay, non-functionalized biosensors were used as a control. To measure the
interaction between IL-7Ra and the TSLP:TSLPR complex, TSLP-loaded sensor
tips were incubated with 320 nM of TSLPR which was also included in the assay
buffer and all IL-7Ra samples. The sensor traces from zero concentration samples
were subtracted from the raw data traces before data analysis. To correct for bulk
effects during the measurements forthe interaction between IL-7Ra and TSLPR a
column of non-functionalized sensors was used to enable double reference sub-
traction. All data were ﬁtted with the Forte´Bio Data Analysis 9.0.0.4 software using
a 1:1 ligand model.
Small-angle X-ray scattering data collection and analysis. SAXS data were
measured on the SWING beam line at the SOLEIL Synchrotron (Gif-sur-Yvette,
France). Around 50ml of glycan-minimized ternary TSLPD127–131:TSLPRN47Q:IL-
7Ra complex (6mgml 1), as prepared for crystallographic studies, was injected
onto an Agilent 4.6 300mm Bio SEC-3 column with 300Å pore size and HBS
pH 7.4 as running buffer at a ﬂow speed of 0.2mlmin 1 at 288 K. X-ray scattering
data were collected in continuous ﬂow mode with 1 s exposure time per frame and
an acquisition rate of 1 frame every 2 s. Data were recorded within a momentum
transfer range of 0.01 Å 1oqo0.6 Å 1, with q¼ 4psiny/l. Raw data were
radially averaged and buffer subtracted using Foxtrot v3.2.7 (developed at Syn-
chrotron SOLEIL and provided by Xenocs (Sassenage, France)). The quality of the
data was analysed with Foxtrot by checking the stability of the radius of gyration
over the length of the elution peak and by scaling all curves to the most intense
scattering proﬁle. The ﬁnal scattering curve was obtained by averaging the
unscaled, buffer-subtracted scattering proﬁles from frames 119–128, which corre-
spond to the top of the elution peak. Structural parameters were determined with
the ATSAS suite76.
Constructs for cellular activity assays and binding studies. The pMET7-
TSLPR127A/R130S-SEAP-Flag allows the expression of a human TSLP-secreted alka-
line phosphatase fusion protein (TSLP-SEAP). pMET7-TSLPR127A/R130S-SEAP-Flag
was created by ligating a codon optimized cDNA fragment for TSLPR127A/R130S with
a C-terminal GGSGGS linker into the EcoRI/BglII opened pMET7-CRH2-SEAP-
Flag vector using primers 22 and 23 (Supplementary Table 5). pMET7-Flag-TSLPR
and pMET7-HA-IL-7Ra allow the expression of full-length FLAG-tagged human
TSLPR and HA-tagged human IL-7Ra. pMET7-Flag-TSLPR was created by ligating
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a codon optimized hTSLPR cDNA-fragment into the ClaI/XbaI opened pMet7-ﬂag-
mTSLP vector37. pMET7-HA-IL-7Ra was created by ligating a codon optimized hIL-
7Ra cDNA fragment into the BspEI/XbaI opened pMet7-HA-mouseIL7Ra vector37.
Site-directed mutations in these vectors were introduced via the Quickchange
protocol (Stratagene). Site-directed mutations of pHL-hTSLPR127A/R130S were ﬁrst
introduced in the pUC57-hTSLP vector via the Quickchange protocol, followed by
ligation of the EcoRI/KpnI mutant hTSLP DNA fragment into the EcoRI/KpnI
opened pHL-hTSLPR127A/R130S vector37. All primers used for site-directed
mutagenesis of human TSLP, TSLPR and IL-7Ra are provided in Supplementary
Table 6.
Competitive TSLP-SEAP cell binding assay. HEK293T cells were transfected
with pMET7-TSLPR127A/R130S-SEAP using linear PEI (Polysciences). The culture
medium was replaced with Optimem medium (Life technologies) one day after
transfection, and the medium containing secreted TSLP-SEAP fusion protein was
harvested three days after transfection. For expression of human TSLPR, HEK293T
cells were transfected with 0.875 ng pMET7 vector and 0.125 ng pMet7-FLAG-
TSLPR per well in 6-well plates using linear PEI (Polysciences). Two days after
transfection, the cells were detached with 5mM EDTA in phosphate buffered saline
(Life Technologies) and were washed in FACS buffer (1% fetal bovine serum,
0.5mM EDTA in phosphate buffered saline). Subsequently, 130,000 cells were
incubated for 2 h at 6 C with TSLP-SEAP containing conditioned medium (diluted
15-fold) and different concentrations of unlabelled wild type or mutant TSLP in
FACS buffer. The concentration of wild type and mutant TSLP was determined by
ELISA (Human TSLP Duoset ELISA, R&D Systems). The cells were washed three
times with FACS buffer, and were used to quantify the amount of bound alkaline
phosphatase activity using the PhosphaLight kit (Tropix) in an Envision chemi-
luminescence counter (Perkin-Elmer). The data were plotted and ﬁtted to a log
inhibitor versus response curve as implemented in Graphpad Prism.
TSLP induced STAT5 reporter activation. For comparing wild type and mutant
TSLP, HEK293T cells were co-transfected with 15 ng pMET7-Flag-TSLPR, 15 ng
pMET7-HA-IL-7Ra, 900 ng empty pMET7 vector and 100 ng pGL3-b-casein-luci
reporter plasmid per well of a 6-well plate. When comparing wild type and mutant
receptors, HEK293T cells were co-transfected with 150 ng pMET7-Flag-hTSLPR,
150 ng pMET7-HA-IL-7Ra, 600 ng empty pMET7 vector and 100 ng pGL3-b-
casein-luci reporter plasmid per well of a 6-well plate. The pGL3-b-casein-luci
luciferase reporter carries a set of ﬁve repeated STAT5-responsive motifs of the
b-casein promoter. One day after transfection, the cells were detached with cell
dissociation buffer (Life Technologies), and resuspended in DMEMþ 10% fetal
bovine serum. Following counting, 50% of the cells were seeded in a new six-well
plate for FACS analysis, and 2% of the cells were seeded per well in 96 well plates
and stimulated with increasing concentrations of hTSLP. The luciferase activity was
determined on day two after transfection using an Envision chemiluminescence
counter. The fold induction of luciferase activity was calculated by the ratio of the
luminescence signal (cps) from cells stimulated with hTSLP to the signal from the
unstimulated cells. The data were plotted and ﬁtted to a log agonist versus response
curve in Graphpad Prism.
The expression of FLAG-tagged hTSLPR at the cell surface was determined
using a mouse monoclonal anti-FLAG M2 antibody (Sigma) and Alexﬂuor488
labelled goat anti-mouse antibody (Molecular Probes) on a FACSCalibur (BD
Biosciences). HA-tagged hIL-7Ra expression was determined using a FITC-labelled
mouse monoclonal anti-HA antibody (Sigma). A gate was set that distinguishes
between cells with low (background) ﬂuorescence and increased ﬂuorescence. Only
‘gated’ cells with increased ﬂuorescence were used to calculate receptor expression
levels. Relative receptor expression was determined as number of gated cells
multiplied by the mean ﬂuorescence of the gated cells.
IL-7 induced STAT5 reporter activation. HEK293T cells were co-transfected with
1,000 ng pREX-IRES-CD4-gamma common, 2 ng pMET7-HA-IL-7Ra, 200 ng
pMX-IRES-GFP-hJak3, 133 ng empty pMET7 vector and 100 ng pGL3-b-casein-
luci reporter plasmid per well of a 6-well plate. One day after transfection, cells
were detached and seeded in 96 well plate as described above and incubated
overnight with human IL-7. Luciferase activity was measured one day later as
described above. The pREX-IRES-CD4-gamma common and pMX-IRES-GFP-
hJak3 vectors77 were kindly provided by Dr S.N. Constantinescu (Ludwig Institute
for Cancer Research, Belgium).
Inhibition in the TSLP induced STAT5 reporter assay. To study the effect of
different inhibitors (TSLP-traps, receptor ectodomains, anti-TSLP AMG-157 mAb
or derived Fab fragment) on TSLP induced STAT5 reporter assays, HEK293T cells
were seeded and transfected as described above. The day after transfection, the cells
were detached with cell dissociation buffer (Life Technologies), and resuspended in
DMEMþ 10% fetal bovine serum. Approximately 3% of the cells were seeded in
50ml medium per well in 96 well plates. In a separate plate, TSLP produced from
HEK293S-TetR MGAT / cells was incubated in medium with increasing con-
centrations of the inhibitors for 30min at room temperature. After this pre-
incubation, 50 ml of this TSLP-inhibitor mix was added to the seeded cells. The
reported concentrations for inhibitor and TSLP are their ﬁnal concentrations in
this 100ml volume. Cells were incubated overnight with this mixture and STAT5
reporter luciferase activity was measured 24 h after the start of the stimulation. Fold
induction of luciferase activity was calculated by dividing the luminescence signal
(counts per second) of the TSLP stimulated cells by the luminescence signal of the
unstimulated cells. The data were ﬁtted to a log inhibitor versus response curve in
GraphPad Prism.
Inhibition of dendritic cell activation by TSLP antagonists. CD1cþ dendritic
cells (DCs) were puriﬁed from adult blood buffy coats (Red Cross Flanders, Bel-
gium). Peripheral blood mononuclear cells (PBMC) were separated by Ficoll
centrifugation. Cells were then depleted from CD19þ B cells using magnetic beads
(Miltenyi Biotec). The negative fraction was then enriched for CD1cþ dendritic
cells by labelling them with anti-CD1c biotinylated antibodies (1:15 dilution),
followed by anti-biotin microbeads (Myltenyi Biotec). CD1cþ DCs were cultured
immediately after puriﬁcation in RPMI containing 10% fetal calf serum (FCS), and
penicillin-streptomycin. Cells were seeded at 0.5 106 per ml in ﬂat-bottomed 96-
well plates in the presence of E. coli-derived human TSLP at 10 pM, or TSLP-trap1,
TSLP-trap2 or AMG-157 mAb at 3 and 10 pM. As controls, medium or medium
supplemented with TSLP-trap1, or TSLP-trap2, or AMG-157 mAb at 30 pM were
included. After 24 h in culture, DCs were collected and stained with anti-human
CD40, CD80 and HLA-DR (all from BD Biosciences). Cells were analysed with a
LSRII Fortessa ﬂow cytometer (BD Biosciences). Dead cells were excluded based on
DAPI positivity. Results were analysed with FlowJo software. DC culture super-
natants were collected at 24 h, and analysed for the presence of CCL17 using a
speciﬁc ELISA (R&D Systems). Endotoxins were removed from recombinant
proteins with e-poly-L-lysine spin columns (Pierce). Resulting endotoxin-levels
were determined with an Endosafe-PTS system (Charles River) as lower than
5–8 EUmg 1 recombinant protein.
Nuclear magnetic resonance. Isotopically labelled 15N-TSLPD127–131 and
13C/15N-TSLPD127–131 were produced in E. coli BL21(DE3) cells transformed with
the pET15b-TSLPD127–131 expression construct (see above). Cells were grown in
minimal medium at 37 C supplemented with a 1 MEM vitamin solution (Sigma
Aldrich, M6895), 1 g l 1 15NH4Cl (Sigma Aldrich, 2,99,251), 3.5 g l 1 U-13C6-
glucose (EURISO-TOP, CLM-1396) and induced with 1mM IPTG. Isotopically
labelled TSLPD127–131 was refolded from inclusion bodies and its N-terminal His-
tag was removed as described above. Protein samples for NMR measurements at
concentrations of 582 mM (8.5mgml 1) for 15N-TSLPD127–131 and 628mM
(9.2mgml 1) for 13C/15N-TSLPD127–131 were prepared in 20mM NaH2PO4 pH
6.8, 50mM NaCl, 2.5mM EDTA and 1 cOmplete Protease Inhibitor cocktail.
NMR spectra were recorded on 600MHz Bruker and 900MHz US2 Bruker NMR
spectrometer instruments at the CNRS Structural and Functional Glycobiology
Unit (Parc Scientiﬁque de la Haute Borne, Lille, France) and assignment of the
triple resonance NMR spectra of TSLP was obtained by the product-plane
approach78. Assignment of the tryptophan side chains was based on the NOE
contact between the tryptophan amide resonance previously assigned by triple
resonance spectroscopy and the Hd side chain proton of tryptophan.
Molecular dynamics simulations. TSLP conformational plasticity. The con-
formational plasticity of TSLP and TSLP bound to TSLPR was investigated by
molecular dynamics simulations. As X-ray structures for TSLP do not provide any
density in the loop region spanning from residues 115–132, ﬁfty models were
generated for this region using Modeller 9.14 (ref. 79). To account for the structural
heterogeneity of this loop, ﬁve diverse loop models were selected for molecular
dynamics simulations. The apo-TSLP structures and TSLP:TSLPR complex
structures were prepared separately. Five 250 ns molecular dynamics simulations,
each with a different TSLP starting model, were performed for TSLP and
TSLP:TSLPR (10 runs in total). All simulations were performed using Gromacs
5.1.1 (ref. 80) with the Amber99SB-ILDN force ﬁeld and TIP3P explicit solvent.
The crystal structure was placed in a rhombic dodecahedron extending 1.2 nm
beyond the diameter of the system. An integration time step of 2 fs and the Verlet
scheme were used for all simulations. Van der Waals and short-range Coulomb
forces were truncated to 10Å. Long-range Coulomb forces were treated with the
particle mesh Ewald method and bonds involving hydrogen atoms were
constrained. During equilibration, protein heavy atoms were harmonically
restrained with a force constant of 1,000 kJmol 1 nm 1. The crystal structure was
relaxed using a steepest descent algorithm until the maximum force exerted on any
atom was lower than 1,000 kJmol 1. A 300 ps NVT equilibration was then
performed, starting at 30K and increasing the temperature to 300 K over the course
of 200 ps. Temperature control was achieved through two Bussi–Parinello ther-
mostats coupled to protein and non-protein groups, each with a coupling time of
0.1 ps. Following NVT equilibration the system was coupled to a Berendsen
barostat with a reference pressure of 1 bar and a coupling time of 0.5 ps for 500 ps
of NPT equilibration. The 250 ns long production runs were performed using two
Nose–Hoover thermostats with coupling times of 1 ps and reference temperatures
of 300 K. Pressure control was achieved through a Parinello-Rahman barostat with
a reference pressure of 1 bar and a coupling time of 2 ps. Snapshots were saved
every 100 ps. Root-mean-square ﬂuctuations around the average structure were
calculated for the ﬁnal 100 ns of simulation time.
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Water-stripped TSLP. An interesting feature of the TSLP crystal structure is the
presence of a buried water molecule in the core. During the MD simulations
described above, the buried water molecule remained bound in the protein core. To
assess its structural role further, molecular dynamics simulations were performed
in which the central water molecule was deleted from the starting model. Three
250 ns all-atom molecular dynamics simulations were completed. Spontaneous
rehydration of this cavity through a channel located between the B and C helices by
bulk water molecules was observed within 15–125 ns in each of three independent
simulations.
Inserted water molecule at the p-helical turn of TSLP helix A. A stabilizing water
molecule can be observed in the A helix of the TSLP:AMG-157Fab crystal structure.
We sought to investigate if water molecules were present at a similar position in
our simulations by identifying water molecules for which the distance between the
water oxygen, and the Tyr43 carbonyl oxygen and the Lys49 amide nitrogen was
equal to or less than 3.5 Å. Such water molecules were identiﬁed in 19% of frames
over the entire TSLP simulations.
Data availability. Protein Data Bank: Coordinates and structure factors for the
crystal structure of the TSLPD127–131:TSLPRN47Q:IL-7Ra complex and TSLPD127–131:
AMG-157Fab complex have been deposited with accession codes 5J11 and 5J13,
respectively. Other PDB codes used in this study: 5J12, 4NN5, 3DI2, 4HIE, 4HK0
and 3UP1.
Small Angle Scattering Biological Data Bank: SAXS data and coordinates of the
best TSLPD127–131:TSLPRN47Q:IL-7Ra model generated by the AllosMod-FoXS
server have been deposited with accession code SASDB99.
Protein sequences used in this study: Thymic stromal lymphopoietin (TSLP):
NCBI NP_149024.1; Thymic stromal lymphopoietin receptor (TSLPR): NCBI
NP_071431.2 and Uniprot ID Q9HC73; Interleukin-7 (IL-7): NCBI NP_000871.1;
Interleukin-7 receptor a (IL-7Ra): NCBI NP_002176.2 and Uniprot ID P16871;
Secreted alkaline phosphatase (SEAP): Uniprot P05187; Bovine Serum Albumine
(BSA): Uniprot ID P02769; Bifunctional ligase/repressor BirA (BirA) UniprotID:
L3K9G4. All other data are available from the corresponding author on reasonable
request.
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